Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Aims Self-monitoring of blood glucose (SMBG) represented a major breakthrough in the treatment of type 1 diabetes. The aim of the present meta-analysis is to assess the effect of continues glucose monitoring (CGM) and flash glucose monitoring (FGM), on glycemic control in type 1 diabetes. Materials and methods The present analysis includes randomized clinical trials comparing CGM or FGM with SMBG, with a duration of at least 12 weeks, identified in Medline or clinicaltrials.gov. The principal endpoint was HbA1c at the end of the trial. A secondary endpoint was severe hypoglycemia. Mean and 95% confidence intervals for HbA1c and Mantel-Haenzel odds ratio [MH-OR] for severe hypoglycemia were calculated, using random effect models. A sensitivity analysis was performed using fixed effect models. In addition, the following secondary endpoints were explored, using the same methods: time in range, health-related quality of life, and treatment satisfaction. Separate analyses were performed for trials comparing CGM with SMBG, and those comparing CGM + CSII and SMBG + MDI and CGM-regulated insulin infusion system (CRIS) and CSII + SMBG. Results CGM was associated with a significantly lower HbA1c at endpoint in comparison with SMBG (- 0.24 [- 0.34, - 0.13]%); CGM was associated with a significantly lower risk of severe hypoglycemia than SMBG. Treatment satisfaction and quality of life were not measured, or not reported, in the majority of studies. FGM showed a significant reduction in t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two reviews [23, 34] evaluated the effect of CGM versus SMBG on DKA risk, with no statistically significant differences observed between intervention and control groups.”
From Effectiveness of Wearable Devices for Diabetes Management: An Overview of Systematic Reviews and Meta‐Analyses (2026) · cites this paper as [34]
In the citing paper
“Regarding DKA prevention, no significant differences have been observed between intervention and control groups [23, 34]”
From Effectiveness of Wearable Devices for Diabetes Management: An Overview of Systematic Reviews and Meta‐Analyses (2026) · cites this paper as [34]
In the citing paper
“Despite the several RCTs demonstrating benefits of various CGM technologies, uncertainty has persisted regarding their comparative effectiveness across different outcomes, patient subgroups, and technology types [40,41].”
From Effectiveness of continuous glucose monitoring systems on glycemic control in adults with type 1 diabetes: A systematic review and meta-analysis (2025) · cites this paper as [40]
In the citing paper
“However, while the use of CGM systems has been shown to (further) improve therapy for people with T1DM [12, 13], mixed results have been reported on the use of CGM systems by people with T2DM [14, 15].”
From Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus (2022) · cites this paper as [12]
In the citing paper
“A lot of clinical [ 4 , 5 ] and real-world studies [ 6 ], as well as systematic reviews and meta-analyses [ 7 , 8 ], have clearly proven the beneficial effect of CGM on glycemic control optimization.”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667 · cited 1×
“Frequent self-monitoring was one of the key components of intensified diabetes therapy in the Diabetes Control and Complication Trial, which warranted a relevant reduction in long-term complications of diabetes [1].”
BackgroundGRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 2×
“Only two trials with a duration of at least 12 weeks compared a CRIS with SMBG + CSII [13, 39].”
MethodLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 2×
“The wider use of CGM devices prompted also the introduction of new potential parameters for the assessment of glucose control, such as glycemic variability (often expressed as coefficient of variation or mean amplitude of glucose excursions), and time in range [9].”
BackgroundState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 1×
“Notably, FGM did not reduce HbA1c in patients with type 2 diabetes on basal-bolus insulin therapy, despite higher baseline HbA1c values [48], whereas CGM improved glycemic control in patients with similar characteristics [49].”
BackgroundDeiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
the SWITCH Study Group, Battelino, T., Conget, I., Olsen, B., Schütz-Fuhrmann, I., Hommel, E., Hoogma, R., Schierloh, U., Sulli, N., & Bolinder, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2708-9 · Cited by 494
Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes
Battelino, T., Phillip, M., Bratina, N., Nimri, R., Oskarsson, P., & Bolinder, J. (2011) · Diabetes Care · doi:10.2337/dc10-1989 · Cited by 490
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463 · cited 1×
“Current research is focused on the development of integrated systems in which the insulin infusion rate is regulated by a CGM sensor, to create a sort of artificial pancreas [8].”
BackgroundLy, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
van Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386
Sensor-Augmented Insulin Pump Therapy: Results of the First Randomized Treat-to-Target Study
Hirsch, I. B., Abelseth, J., Bode, B. W., Fischer, J. S., Kaufman, F. R., Mastrototaro, J., Parkin, C. G., Wolpert, H. A., & Buckingham, B. A. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0068 · Cited by 297
Continuous glucose monitoring systems for type 1 diabetes mellitus
Langendam, M., Luijf, Y. M., Hooft, L., DeVries, J. H., Mudde, A. H., & Scholten, R. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008101.pub2 · Cited by 262
Reddy, M., Jugnee, N., El Laboudi, A., Spanudakis, E., Anantharaja, S., & Oliver, N. (2018) · Diabetic Medicine · doi:10.1111/dme.13561 · Cited by 245
Šoupal, J., Petruželková, L., Grunberger, G., Hásková, A., Flekač, M., Matoulek, M., Mikeš, O., Pelcl, T., Škrha, J., Horová, E., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0888 · Cited by 242
Raccah, D., Sulmont, V., Reznik, Y., Guerci, B., Renard, E., Hanaire, H., Jeandidier, N., & Nicolino, M. (2009) · Diabetes Care · doi:10.2337/dc09-0750 · Cited by 237
O’Connell, M. A., Donath, S., O’Neal, D. N., Colman, P. G., Ambler, G. R., Jones, T. W., Davis, E. A., & Cameron, F. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1365-0 · Cited by 211
Mauras, N., Beck, R., Xing, D., Ruedy, K., Buckingham, B., Tansey, M., White, N. H., Weinzimer, S. A., Tamborlane, W., Kollman, C., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1746 · Cited by 204
Hermanides, J., Nørgaard, K., Bruttomesso, D., Mathieu, C., Frid, A., Dayan, C. M., Diem, P., Fermon, C., Wentholt, I. M. E., Hoekstra, J. B. L., et al. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03256.x · Cited by 169
Flash forward: a review of flash glucose monitoring
Leelarathna, L., & Wilmot, E. G. (2018) · Diabetic Medicine · doi:10.1111/dme.13584 · Cited by 167
Beck, R. W., Riddlesworth, T. D., Ruedy, K. J., Kollman, C., Ahmann, A. J., Bergenstal, R. M., Bhargava, A., Bode, B. W., Haller, S., Kruger, D. F., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30217-6 · Cited by 119
Ólafsdóttir, A. F., Polonsky, W., Bolinder, J., Hirsch, I. B., Dahlqvist, S., Wedel, H., Nyström, T., Wijkman, M., Schwarcz, E., Hellman, J., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0363 · Cited by 113
Pala, L., Dicembrini, I., & Mannucci, E. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01326-5 · Cited by 112
Self-citationTumminia, A., Crimi, S., Sciacca, L., Buscema, M., Frittitta, L., Squatrito, S., Vigneri, R., & Tomaselli, L. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2557 · Cited by 100
Riveline, J.-P., Schaepelynck, P., Chaillous, L., Renard, E., Sola-Gazagnes, A., Penfornis, A., Tubiana-Rufi, N., Sulmont, V., Catargi, B., Lukas, C., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2021 · Cited by 94
Paris, I., Henry, C., Pirard, F., Gérard, A., & Colin, I. M. (2018) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.23 · Cited by 84 · cited 1×
“This shows that the increased frequency of glucose monitoring is sufficient to reduce hypoglycemic risk, even in the absence of alarms, confirming data retrieved from observational studies [47].”
First Look at Control-IQ: A New-Generation Automated Insulin Delivery System
Brown, S., Raghinaru, D., Emory, E., & Kovatchev, B. (2018) · Diabetes Care · doi:10.2337/dc18-1249 · Cited by 82
New, J. P., Ajjan, R., Pfeiffer, A. F. H., & Freckmann, G. (2015) · Diabetic Medicine · doi:10.1111/dme.12713 · Cited by 80
Zhong, A., Choudhary, P., McMahon, C., Agrawal, P., Welsh, J. B., Cordero, T. L., & Kaufman, F. R. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0216 · Cited by 77
Lagarde, W. H., Barrows, F. P., Davenport, M. L., Kang, M., Guess, H. A., & Calikoglu, A. S. (2006) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2006.00162.x · Cited by 72
Boscari, F., Galasso, S., Facchinetti, A., Marescotti, M. C., Vallone, V., Amato, A. M. L., Avogaro, A., & Bruttomesso, D. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.10.023 · Cited by 72
Floyd, B., Chandra, P., Hall, S., Phillips, C., Alema-Mensah, E., Strayhorn, G., Ofili, E. O., & Umpierrez, G. E. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600513 · Cited by 70
Flash Glucose Monitoring: A Review of the Literature with a Special Focus on Type 1 Diabetes
Mancini, G., Berioli, M. G., Santi, E., Rogari, F., Toni, G., Tascini, G., Crispoldi, R., Ceccarini, G., & Esposito, S. (2018) · Nutrients · doi:10.3390/nu10080992 · Cited by 70
Peyrot, M., & Rubin, R. R. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0002 · Cited by 68
Benkhadra, K., Alahdab, F., Tamhane, S., Wang, Z., Prokop, L. J., Hirsch, I. B., Raccah, D., Riveline, J.-P., Kordonouri, O., & Murad, M. H. (2017) · Clinical Endocrinology · doi:10.1111/cen.13290 · Cited by 66
Continuous glucose monitoring pilot in low-income type 1 diabetes patients
Sequeira, P. A., Montoya, L., Ruelas, V., Xing, D., Chen, V., Beck, R., & Peters, A. L. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0072 · Cited by 59
Dicembrini, I., Mannucci, E., Monami, M., & Pala, L. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13845 · Cited by 46
Self-citationAleppo, G., & Webb, K. M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0097 · Cited by 44
Imperatori, C., Mancini, M., Della Marca, G., Valenti, E. M., & Farina, B. (2018) · Nutrients · doi:10.3390/nu10111806 · Cited by 43
[Normal indicators of the cardiovascular system in laboratory animals (rats)].
Muzurov, I. V., Vn, V., & Roshchevskaia, N. I. (1989) · PubMed · Cited by 43
Kordonouri, O., Hartmann, R., Pańkowska, E., Rami-Merhar, B. M., Kapellen, T. M., Coutant, R., Lange, K., & Danne, T. (2012) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2012.00863.x · Cited by 35
Wan, W., Skandari, M. R., Minc, A., Nathan, A. G., Zarei, P., Winn, A. N., O’Grady, M. J., & Huang, E. S. (2018) · Medical Decision Making · doi:10.1177/0272989x18803109 · Cited by 26
Factors Associated with Adherence to Continuous Subcutaneous Insulin Infusion in Pediatric Diabetes
Babar, G., Ali, O., Parton, E. A., Hoffmann, R. G., & Alemzadeh, R. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0042 · Cited by 25
Sensor-augmented pump therapy in type 1 diabetes
WEINZIMER, S. A., & Tamborlane, W. V. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f7960b · Cited by 24
Dicembrini, I., Pala, L., Caliri, M., Minardi, S., Cosentino, C., Monami, M., & Mannucci, E. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14028 · Cited by 22
Self-citationGuilmin‐Crépon, S., Carel, J., Schroedt, J., Sulmont, V., Salmon-Musial, A. S., Tallec, C. L., Coutant, R., Dalla‐Vale, F., Stuckens, C., Bony-Trifunovic, H., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12820 · Cited by 18
Olivier, P., Lawson, M. L., Huot, C., Richardson, C., Nakhla, M. M., & Romain, J. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814524855 · Cited by 12
Glycaemia Control in Diabetes Mellitus: Towards The Normal Profile?
Zimmerman, B. R. (1994) · Drugs · doi:10.2165/00003495-199447040-00005 · Cited by 6
Šoupal, J., & Parkin, C. G. (2020) · Diabetes Care · doi:10.2337/dci20-0005 · Cited by 3
Cited by
Teo, E., Hassan, N., Tam, W., & Koh, S. (2022) · Diabetologia · doi:10.1007/s00125-021-05648-4 · Cited by 186
Elbalshy, M., Haszard, J., Smith, H., Kuroko, S., Galland, B., Oliver, N., Shah, V., de Bock, M. I., & Wheeler, B. J. (2022) · Diabetic Medicine · doi:10.1111/dme.14854 · Cited by 104
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring
Tauschmann, M., Forlenza, G., Hood, K., Cardona‐Hernandez, R., Giani, E., Hendrieckx, C., DeSalvo, D. J., Laffel, L. M., Saboo, B., Wheeler, B. J., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13451 · Cited by 100
New advances in type 1 diabetes
Subramanian, S., Khan, F., & Hirsch, I. B. (2024) · BMJ · doi:10.1136/bmj-2023-075681 · Cited by 88
Di Molfetta, S., Di Gioia, L., Caruso, I., Cignarelli, A., Green, S. C., Natale, P., Strippoli, G. F. M., Sorice, G. P., Perrini, S., Natalicchio, A., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3842 · Cited by 76
Metadata
- Authors
- Dicembrini, I., Cosentino, C., Monami, M., Mannucci, E., & Pala, L.
- Affiliations
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Corresponding author
- Pala, L.
- Venue
- Acta Diabetologica
- Published
- 2020-08-13
- Volume
- 58
- Issue
- 4
- Pages
- 401-410
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W3049019930
- Cited by
- 106
- References
- 55
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 22 · 2023: 23 · 2022: 25 · 2021: 7
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, continuous glucose monitoring, flash glucose monitoring, self-monitoring of blood glucose, glycemic control, HbA1c, severe hypoglycemia, insulin pump therapy, multiple daily insulin injections, time in range, health-related quality of life, treatment satisfaction
- MeSH terms
- Glycemic Control, Adult, Blood Glucose, Computer Systems, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Quality of Life, Blood Glucose Self-Monitoring, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.